Obviousness and Pharmaceutical Method of Treatment Claims
Patently O
APRIL 1, 2024
Of relevance for the case, one of the dependent claims (19) includes a requirement of a particular particle size: dosing “consists essentially of … 156 mg/ml of the paliperidone palmitate having an average particle size (d50) of from about 1600 nm to about 900 nm.”
40 
Let's personalize your content